Cargando…
Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents
Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443334/ https://www.ncbi.nlm.nih.gov/pubmed/32846329 http://dx.doi.org/10.1016/j.biopha.2020.110643 |
_version_ | 1783573614703935488 |
---|---|
author | Su, Li Tu, Ye Kong, De-pei Chen, Da-gui Zhang, Chen-xi Zhang, Wan-nian Zhuang, Chun-lin Wang, Zhi-bin |
author_facet | Su, Li Tu, Ye Kong, De-pei Chen, Da-gui Zhang, Chen-xi Zhang, Wan-nian Zhuang, Chun-lin Wang, Zhi-bin |
author_sort | Su, Li |
collection | PubMed |
description | Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS. |
format | Online Article Text |
id | pubmed-7443334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Author(s). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74433342020-08-24 Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents Su, Li Tu, Ye Kong, De-pei Chen, Da-gui Zhang, Chen-xi Zhang, Wan-nian Zhuang, Chun-lin Wang, Zhi-bin Biomed Pharmacother Short Communication Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS. The Author(s). Published by Elsevier Masson SAS. 2020-11 2020-08-23 /pmc/articles/PMC7443334/ /pubmed/32846329 http://dx.doi.org/10.1016/j.biopha.2020.110643 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Su, Li Tu, Ye Kong, De-pei Chen, Da-gui Zhang, Chen-xi Zhang, Wan-nian Zhuang, Chun-lin Wang, Zhi-bin Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents |
title | Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents |
title_full | Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents |
title_fullStr | Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents |
title_full_unstemmed | Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents |
title_short | Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents |
title_sort | drug repurposing of anti-infective clinical drugs: discovery of two potential anti-cytokine storm agents |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443334/ https://www.ncbi.nlm.nih.gov/pubmed/32846329 http://dx.doi.org/10.1016/j.biopha.2020.110643 |
work_keys_str_mv | AT suli drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents AT tuye drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents AT kongdepei drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents AT chendagui drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents AT zhangchenxi drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents AT zhangwannian drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents AT zhuangchunlin drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents AT wangzhibin drugrepurposingofantiinfectiveclinicaldrugsdiscoveryoftwopotentialanticytokinestormagents |